Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
2.240
-0.020 (-0.88%)
At close: Sep 4, 2026, 4:00 PM EDT
2.260
+0.020 (0.89%)
After-hours: Sep 4, 2026, 7:59 PM EDT
Lexicon Pharmaceuticals Revenue
Lexicon Pharmaceuticals had revenue of $692.00K in the quarter ending June 30, 2026, a decrease of -97.60%. This brings the company's revenue in the last twelve months to $41.47M, down -29.03% year-over-year. In the year 2025, Lexicon Pharmaceuticals had annual revenue of $49.80M with 60.24% growth.
Revenue (ttm)
$41.47M
Revenue Growth
-29.03%
P/S Ratio
24.03
Revenue / Employee
$511,963
Employees
81
Market Cap
996.70M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 49.80M | 18.72M | 60.24% |
| Dec 31, 2024 | 31.08M | 29.88M | 2,481.48% |
| Dec 31, 2023 | 1.20M | 1.07M | 766.19% |
| Dec 31, 2022 | 139.00K | -159.00K | -53.36% |
| Dec 31, 2021 | 298.00K | -23.70M | -98.76% |
| Dec 31, 2020 | 24.00M | -298.08M | -92.55% |
| Dec 31, 2019 | 322.07M | 258.86M | 409.54% |
| Dec 31, 2018 | 63.21M | -28.48M | -31.06% |
| Dec 31, 2017 | 91.69M | 12.43M | 15.69% |
| Dec 31, 2016 | 79.26M | -50.76M | -39.04% |
| Dec 31, 2015 | 130.01M | 107.16M | 468.89% |
| Dec 31, 2014 | 22.85M | 20.63M | 928.53% |
| Dec 31, 2013 | 2.22M | 1.13M | 104.04% |
| Dec 31, 2012 | 1.09M | -760.00K | -41.10% |
| Dec 31, 2011 | 1.85M | -3.06M | -62.33% |
| Dec 31, 2010 | 4.91M | -5.79M | -54.13% |
| Dec 31, 2009 | 10.70M | -21.62M | -66.89% |
| Dec 31, 2008 | 32.32M | -17.80M | -35.51% |
| Dec 31, 2007 | 50.12M | -22.68M | -31.15% |
| Dec 31, 2006 | 72.80M | -2.88M | -3.81% |
| Dec 31, 2005 | 75.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Geron | 204.56M |
| Arbutus Biopharma | 181.72M |
| Wave Life Sciences | 65.37M |
| Adlai Nortye Group | 18.06M |
| Avalo Therapeutics | 59.00K |
LXRX News
- 6 days ago - Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences - GlobeNewsWire
- 7 days ago - Lexicon announces results from post hoc analysis of SOLOIST-WHF trial - TheFly
- 7 days ago - Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure - GlobeNewsWire
- 14 days ago - Lexicon earns third $10M milestone payment from Novo Nordisk for LX9851 - TheFly
- 14 days ago - Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851 - GlobeNewsWire
- 4 weeks ago - Lexicon reports Q2 EPS (7c), consensus (5c) - TheFly
- 4 weeks ago - Lexicon Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 4 weeks ago - Lexicon Pharmaceuticals Earnings release: Q2 2026 - Filings